Adc Therapeutics SA (ADCT)

NYSE
7.51
+0.46(+6.52%)
After Hours
7.51
0.00(0.00%)
- Real-time Data
  • Volume:
    139,397
  • Day's Range:
    7.00 - 7.53
  • 52 wk Range:
    6.18 - 32.00

ADCT Overview

Prev. Close
7.05
Day's Range
7-7.53
Revenue
80.42M
Open
7.2
52 wk Range
6.18-32
EPS
-2.54
Volume
139,397
Market Cap
576.85M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
208,432
P/E Ratio
-
Beta
-
1-Year Change
-64.14%
Shares Outstanding
76,810,477
Next Earnings Date
Aug 23, 2022
What is your sentiment on Adc Thera?
or
Market is currently closed. Voting is open during market hours.

Adc Therapeutics SA News

  • ADC Therapeutics SA Tops Q1 EPS by 34c
    • ByInvesting.com-

    ADC Therapeutics SA (ADCT) reported Q1 EPS of ($0.36), $0.34 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $46.5 million versus the consensus...

Adc Therapeutics SA Company Profile

Adc Therapeutics SA Company Profile

Employees
0

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • ofc
    0
    • Looks good!
      0